KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gilead Sciences (GILD) EBIT (2016 - 2026)

Gilead Sciences filings provide 17 years of EBIT readings, the most recent being $2.0 billion for Q4 2025.

  • On a quarterly basis, EBIT fell 19.09% to $2.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $10.0 billion, a 503.01% increase, with the full-year FY2025 number at $10.0 billion, up 503.01% from a year prior.
  • EBIT hit $2.0 billion in Q4 2025 for Gilead Sciences, down from $3.3 billion in the prior quarter.
  • In the past five years, EBIT ranged from a high of $3.8 billion in Q3 2021 to a low of -$4.3 billion in Q1 2024.
  • Median EBIT over the past 5 years was $2.2 billion (2021), compared with a mean of $1.8 billion.
  • Biggest five-year swings in EBIT: surged 765.48% in 2023 and later tumbled 353.49% in 2024.
  • Gilead Sciences' EBIT stood at $940.0 million in 2021, then skyrocketed by 141.17% to $2.3 billion in 2022, then decreased by 28.89% to $1.6 billion in 2023, then surged by 52.11% to $2.5 billion in 2024, then decreased by 19.09% to $2.0 billion in 2025.
  • The last three reported values for EBIT were $2.0 billion (Q4 2025), $3.3 billion (Q3 2025), and $2.5 billion (Q2 2025) per Business Quant data.